Advertisement

TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients

  • Ellen Boswijk
  • Karin J. C. Sanders
  • Evie P. M. Broeders
  • Marlies de Ligt
  • Guy H. E. J. Vijgen
  • Bas Havekes
  • Alma M. A. Mingels
  • Roel Wierts
  • Wouter D. van Marken Lichtenbelt
  • Patrick Schrauwen
  • Felix M. Mottaghy
  • Joachim E. Wildberger
  • Jan BuceriusEmail author
Open Access
Original Article

Abstract

Purpose

We aimed to investigate the influence of both hypothyroidism and thyroid-stimulating hormone (TSH) suppression on vascular inflammation, as assessed with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT).

Methods

Ten thyroid carcinoma patients underwent an 18F-FDG PET/CT during post-thyroidectomy hypothyroidism and during thyrotropin (TSH) suppression after 131I (radioiodine) ablation therapy. We analysed the 18F-FDG uptake in the carotids, aortic arch, ascending, descending, and abdominal aorta to investigate the effects of thyroid hormone status on arterial inflammation. Target-to-background ratios (TBRs) corrected for blood pool activity were established for all arterial territories. Results were further compared to euthyroid historic control subjects.

Results

In general, there was a trend towards higher vascular TBRs during TSH suppression than during hypothyroidism (TBRmax all vessels = 1.6 and 1.8, respectively, p = 0.058), suggesting a higher degree of arterial inflammation. In concurrence with this, we found increased C-reactive protein (CRP) levels after levothyroxine treatment (CRP = 2.9 mg/l and 4.8 mg/l, p = 0.005). An exploratory comparison with euthyroid controls showed significant higher TBRs during TSH suppression for the carotids, aortic arch, thoracic descending aorta, and when all vascular territories were combined (TBRmaxp = 0.013, p = 0.016, p = 0.030 and p = 0.018 respectively).

Conclusions

Arterial inflammation is increased during TSH suppression. This finding sheds new light on the underlying mechanism of the suspected increased risk of cardiovascular disease in patients with TSH suppression.

Keywords

Positron emission tomography (PET) Thyroid disease Atherosclerosis Inflammation TSH suppression 

Abbreviations

18F-FDG

18F-fluorodeoxyglucose

BAT

Brown adipose tissue

BM

Bone marrow

CAC score

Coronary artery calcium score

CRP

C-reactive protein

CT

Computed tomography

DTC

Differentiated thyroid carcinoma

FFA

Free fatty acids

fT4

Free thyroxin

GLUT

Glucose transporter

JV

Jugular vein

PET

Positron emission tomography

ROI

Region of interest

SAT

Subcutaneous adipose tissue

SUV

Standardized uptake value

SCV

Superior cava vein

TBR

Target-to-background ratio

TSH

Thyroid-stimulating hormone; thyrotropin

VAT

Visceral adipose tissue

WVA

Whole vessel analysis

Background

In order to prevent cardiovascular events, it is necessary to identify subjects with a high risk of developing advanced atherosclerosis. Several clinical risk factors for atherosclerosis and subsequent complications have been identified, such as obesity, hypertension, diabetes, and smoking [1]. A less commonly known risk factor is thyroid hormone imbalance. Although findings for both hypo- and particularly hyperthyroidism have been ambiguous, it is suspected that both influence atherosclerosis negatively, resulting in a U-shaped correlation between thyroid hormone levels and the risk of cardiovascular disease [2]. Since inflammation plays a major role in cardiovascular disease, it could be expected that thyroid hormone status influences atherosclerosis via arterial inflammation.

A commonly used method to image arterial inflammation is 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET). In atherosclerosis, 18F-FDG uptake has been correlated to macrophage content of carotid plaques [3], but also to the presence or the development of symptoms [4, 5]. Additionally, the same technique has proven its value as a non-invasive method to measure the metabolic activity of other tissues, such as hematopoietic organs and subcutaneous and visceral adipose tissue (SAT and VAT) [6, 7]. Arterial inflammation has been correlated to an increased activation in the spleen and the bone marrow (BM) [8, 9] and to the metabolic activity in adipose tissue, most strongly in VAT [6, 7].

Patients with differentiated thyroid carcinoma (DTC) are commonly subjected to both ends of the thyroid hormone spectrum as a result of their therapy [10, 11]. After initial thyroidectomy, patients are left hypothyroid before adjuvant radioactive iodine (I131) ablation to facilitate uptake of radioactive iodine in the remaining thyroid tissue. Whereas thyroid hormone levels drop, thyrotropin [thyroid-stimulating hormone (TSH)] levels rise during this period. Since DTC cells express TSH receptors, high TSH levels will stimulate potential residual malignant tissue proliferation, but also iodine uptake, increasing the effect of I131 ablation [10, 11]. After therapy, patients are subscribed long-term levothyroxine treatment to induce a state of TSH suppression to prevent further stimulation of possible residual malignant tissue [10, 11, 12]. However, recent guidelines emphasize a personalized approach, weighing individual risk of recurrent disease against the risk of adverse effects of TSH suppression [10, 11, 12, 13].

We aimed to investigate the influence of thyroid function on vascular inflammation, as assessed with 18F-FDG PET / computed tomography (CT). For this purpose, we analysed data from a prospective observational study on the effects of thyroid hormone on cold-induced brown adipose tissue (BAT) activation by 18F-FDG PET/CT in ten patients with DTC during both iatrogenic hypothyroidism and TSH suppression.

Methods

DTC subjects

Ten patients with DTC (papillary, n = 7; follicular, n = 3: two males and eight females) were included between June 2012 and July 2014. All patients were screened on their ability to comply with the study protocol, and all female patients had to be either postmenopausal or using a specific oral contraceptive pill to ensure stable sex hormone status. Exclusion criteria were insulin-dependent type 2 diabetes or diabetes-related complications, the use of β-blockers, pregnancy, recent participation in an intensive weight-loss program, and alcohol and/or drug abuse. The protocol was approved by the local medical ethics committee. All participants underwent two 18F-FDG PET/CT scans to study cold-induced BAT and thus served as their own control. Participants were treated for well-differentiated thyroid carcinoma according to local protocol and the national guideline for diagnosis and treatment of thyroid carcinoma [10]. This advocates thyroid resection, followed by a minimum period of 4 weeks without thyroid hormone replacement (withdrawal phase) to achieve the desired hypothyroidism. The first 18F-FDG PET/CT scan was performed when plasma fT4 levels were at a minimum (on average 6.8 ± 3.2 weeks after surgery, fT4 3.4 ± 0.8 pmol/l, TSH 104.9 ± 53.6 mU/l). During the same time, various measurements were performed to determine energy expenditure (see Broeders et al. [14] for details) and patients were scheduled for radioactive iodine ablation with 131I the same day. The second scan was carried out 4 to 6 months after radioactive iodine ablation therapy (22.7 ± 7.8 weeks), when patients had stable high fT4 and low TSH levels due to levothyroxine supplementation. Levothyroxine dosage had remained unchanged for at least a month before the second scan. The average dose was 143.8 ± 23.8 μg/day and during this period average fT4 and TSH levels were 23.1 ± 3.9 pmol/l and 0.5 ± 0.6 mU/l (range < 0.01–1.7) respectively.

Euthyroid subjects

As euthyroid controls, we used data from placebo scans of eight participants of a crossover study evaluating the effect of resveratrol supplementation on BAT activation in subjects at risk of developing type 2 diabetes [15]. Participants had no known history of thyroid disease or medication that could interfere with thyroid hormones. These participants were included between April 2014 and March 2016. The protocol was approved by the local medical ethics committee. Participants were included primarily based on impaired insulin-sensitivity, defined as a glucose clearance rate of < 350 ml/kg/min according to the oral glucose insulin sensitivity (OGIS120) model, based on a standardized 2-h oral glucose tolerance test (OGTT). Furthermore, all participants were obese, had a sedentary life style, and had first-degree relatives with type 2 diabetes. Similarly to the study protocol of the DTC patients, all participants underwent two 18F-FDG PET/CT scan to study cold-induced BAT; once at the end of a 34-day placebo treatment period, and once at the end of a 34-day resveratrol treatment. Data from the placebo period were used for comparison to the DTC patients. Apart from the placebo treatment, all interventions, such as cold acclimatization protocol, were comparable between these studies. To confirm euthyroid state, fT4 and TSH levels were determined in preserved blood samples. Seven subjects were indeed euthyroid, but one subject had aTSH level in the high-normal range (4.23 mU/l) with a normal fT4. As a value of 4.0 mU/l is frequently considered as the upper limit of TSH normal range, we dicided a priorily to exclude this subject from further analysis to safely avoid any bias to the results.

Laboratory tests

Fasting blood (EDTA plasma) was drawn on the day of either scan in the case of the DTC patients, and on day 30 of placebo treatment for the subjects at risk of developing type 2 diabetes. TSH, fT4, CRP, glucose, and cholesterol levels were analysed. TSH was measured using an electrochemiluminescent immunometric assay (Cobas 6000, Roche Diagnostics, Mannheim, Germany) with a reference range of 0.4–4.3 mU/l. fT4 was measured using a competitive immunofluorimetric assay (AutoDelfia, Perkin Elmer, Turku, Finland) with a reference range of 8–18 pmol/l. CRP was measured using a turbidimetric assay (Cobas 8000) with a reference range of < 10 mg/l and a detection limit of > 1 mg/l. Glucose was measured using a hexokinase-based assay (Cobas 6000) with a reference range of 3.1–7.8 mmol/l. Cholesterol levels were determined using spectrophotometric analysis (reference ranges total cholesterol < 5.0 mmol/l; LDL < 3.0 mmol/l). Plasma free fatty acids (FFA) and total glycerol were measured using enzymatic assays automated on a Cobas Fara/Mira analyser, using Wako Nefa C test kit (Wako Chemicals, Richmond, VA, USA) and Enzytec glycerol kit (R-biopharm, Darmstadt, Germany) respectively.

PET protocol

All subjects underwent the same PET scan protocol which included an overnight fast, a dedicated and personalized cooling protocol, and the injection of a fixed activity of approximately 75 MBq 18F-FDG (details can be found in Broeders et al. [14] and de Ligt et al. [15]). Imaging was performed using a Gemini™ TF PET/CT system (Philips Healthcare, Eindhoven, The Netherlands). Patients underwent a low-dose non-contrast-enhanced whole-body CT protocol (120 kVp, 30 mAs) for scatter and attenuation correction and anatomical reference imaging.

Image analysis

All image analyses were performed on a dedicated commercially available workstation (Extended Brilliance Workspace™ V4.5.3.40140, Philips). Circular regions of interest (ROIs) were manually drawn to encompass the entire artery including the arterial wall and lumen. The aorta was divided into ascending aorta, aortic arch, thoracic descending aorta (until the diaphragm) and abdominal aorta (until the iliac bifurcation or as low as sufficiently imaged).

For each ROI, the measured activity concentration was corrected for radioactive decay, total administered activity, and body weight, resulting in the mean and maximum standardized uptake value, SUVmean and SUVmax, respectively. To normalize for blood pool activity, a target-to-background ratio (TBR) was calculated by dividing the arterial SUVs by the mean SUVmean of at least three standardized circular ROIs (4 mm) placed in the lumen of adjacent veins. The jugular vein (JV) served as a reference for the carotids and the superior cava vein (SCV) for the aorta. All measures for SUVmean and SUVmax were corrected, which led to a corresponding TBRmean and TBRmax respectively. The average of each vascular territory [whole vessel analysis (WVA)] was used for statistical analysis between the two different scans. For the carotid arteries, only the highest value was used for further analysis.

Standardized circular ROIs were also placed in bone marrow (20-mm ROIs placed in the centre of each thoracic and, if imaged, lumbar vertebra), spleen (20-mm ROIs encompassing all transversal slices), visceral (white) adipose tissue (VAT) (three 4-mm ROIs in intra-peritoneal fat around the level of the navel) and subcutaneous adipose tissue (SAT) in the neck (three 4-mm ROIs in the nuchal SAT) and chest (three 4-mm ROIs in SAT at the level of the xiphoid). TBRs were calculated by dividing corresponding SUVs by the mean SUVmean of nearest reference vein (SCV in all cases except for nuchal SAT, where the JV was used).

In general, ROIs were excluded from further analysis, when spill-in of activity from adjacent structures with high uptake was suspected or motion-artefacts interfered with the drawing of representable ROIs.

Statistical analysis

Statistical analysis was performed with IBM SPSS Statistics for Macintosh, version 23 (2015). Descriptive data are presented as mean values with the standard deviation (SD) or as absolute numbers. Because of the small group size, non-parametric tests were used. Continuous variables were compared between treatment periods using the Wilcoxon signed-rank test. The Mann–Whitney U test was used to compare continuous data between hypothyroidism and TSH suppression, with an independent sample of participants serving as a euthyroid controls. The χ2 test was used to compare categorical data between the different groups. Correlations between laboratory results and TBRs were tested using Spearman’s correlation coefficient. A p value of < 0.05 was considered to be statistically significant.

Results

Baseline characteristics and blood analysis

TSH and fT4 blood levels confirmed that all patients were hypothyroid at the time of the first scan (mean TSH 104.9 ± 53.6 mU/l; mean fT4 3.4 ± 0.8 pmol/l). During the second scan, all patients had had stable levothyroxine treatment (mean dose 143.8 ± 23.8 μg/day) for at least 1 month (mean TSH 0.5 ± 0.6 mU/l; fT4 23.1 ± 3.9 pmol/l). TSH was fully suppressed (< 0.01 mU/l) in 4/10 participants, suppressed (0.1 mU/l) in 2/10 and in the low-normal range (0.4–2 mU/l) in 4/10. In all but one patient, fT4 levels were above normal reference values (> 18 pmol/l) at the time of the second scan. One patient had an fT4 value in the high-normal range (14.3 pmol/l) corresponding to a TSH in the low-normal range (0.8 mU/l). Subject weight or injected 18F-FDG-activity did not differ significantly between scan times (see Table 1). CRP levels were detectable (> 1.0 mg/l) in some of the patients (4/10) during hypothyroidism, but during TSH suppression, detectable CRP levels were observed in the majority of patients (6/10), and the mean serum levels were significantly higher during TSH suppression (4.8 mg/l) than during hypothyroidism (2.9 mg/l, p = 0.005). In addition, blood pressure, glucose and plasma lipid levels [free fatty acids (FFA) and glycerol] decreased after levothyroxine treatment (see Table 1).
Table 1

Subject characteristics and laboratory results

 

Hypothyroid

n = 10

TSH suppression

n = 10

P valuea

Euthyroid

n = 7

Age (years)

47.6 (10)**

48.2 (10)**

0.014

62.3 (8)

Sex (males)

2**

NA

NA

7

Weight (kg)

82.3 (15.2)

83.5 (17.3)

0.779

89.6 (5.4)

BMI (kg/m2)

29.2 (5.8)

29.6 (6.6)

0.508

28.5 (2.0)

Overweight (BMI > 25)

8

8

1.000

7

Obese (BMI > 30)

4

4

1.000

1

Hypercholesterolemia b

0**

0**

1.000

6b

MAP (mmHg)

105 (20)

96 (16)

0.025

108 (7)

Hypertension (> 140/90 mmHg)

3*

3*

1.000

6

Smoker

1

1

1.000

0

Injected 18F-FDG activity

72.3 (4.1)

72.8 (4.3)

0.475

75.1 (3.3)

Levothyroxine dose (μg/day)

NA

143.8 (23.8)

NA

NA

TSH (mU/l)

104.9 (53.6)**

0.5 (0.6)**

0.005

2.0 (0.7)

fT4 (pmol/l)

3.4 (0.8)**

23.1 (3.9)**

0.005

14.9 (1.4)

CRP (mg/l)c

2.9 (4.5)

4.8 (5.9)**

0.005

2.64 (1.2)

Glucose (mmol/l)

5.0 (0.6)

5.3 (0.4)

0.028

5.6 (0.5)

Free fatty acids (μmol/l)

734 (166)**

562 (172)*

0.047

372 (152)

Total glycerol (μmol/l)

1554 (291)

967 (486)*

0.007

1615 (525)

Blood pool activity

SUVmean JV

1.4 (0.2)

1.3 (0.3)*

0.026

1.4 (0.2)

SUVmean SCV

1.6 (0.3)

1.3 (0.2)*

0.011

1.6 (0.3)

Bold font indicates a statistically significant difference between hypothyroidism and TSH-suppression.

When applicable, means are given with the standard deviation between brackets, or the absolute number of subjects. None of the thyroid cancer patients had a history of hypercholesterolemia and none used cholesterol-lowering drugs. However, cholesterol levels were only available for n = 2.

Asterisks indicate significant differences compared to euthyroid patients

NA not applicable

*p < 0.05

**p < 0.01

aP values were calculated for differences between hypothyroidism and TSH suppression

bHypercholesterolemia was defined as a total cholesterol > 5.0 mmol/l, or LDL > 3.0 mmol/l. Cholesterol values were available for n = 6 of the euthyroid group

cseven pairs were available for analysis

Blood pool activity was significantly lower after levothyroxine treatment in comparison to hypothyroidism in both the jugular vein as well as the superior cava vein (meanSUVmean jugular vein 1.4 ± 0.2 vs 1.3 ± 0.3, p = 0.026 and mean SUVmean superior cava vein 1.6 ± 0.3 vs 1.3 ± 0.2, p = 0.011).

Since the DTC patients were only scanned during hypothyroidism and TSH suppression, and thus not in the euthyroid state, the results of this study are insufficient to confirm or dismiss a U-shaped correlation between thyroid hormone levels and arterial inflammation. Therefore, we additionally screened our institutional data for euthyroid subjects who underwent a similar scan protocol. Seven euthyroid subjects were included with a mean TSH 2.0 ± 0.7 mU/l and a mean fT4 14.9 ± 1.4 pmol/l. Characteristics of these subjects can be found in Table 1. Most importantly, euthyroid subjects had more cardiovascular risk factors than the DTC patients. They were all obese males with impaired insulin sensitivity. Their average age was older than that of the thyroid cancer patients (62.3 ± 8 years versus 47.6 ± 10 years during the first scan, p = 0.005) and more of them had hypertension (86% vs 30%, p = 0.024) and/or hypercholesterolemia (100% vs 0%, p < 0.001). Blood pool activity in these euthyroid patients was similar to that of the DTC patients during hypothyroidism.

Image quality

In all scans (n = 20 DTC and n = 7 euthyroid subjects), image quality was sufficient to include all aortic regions in the analysis. However, 18F-FDG uptake in both carotids could not be analysed in scans of one DTC and in two euthyroid participants due to motion artefacts and/or spill-in. In two other participants (one DTC and one euthyroid), the ROIs of only one carotid artery were considered representable. For all other subjects, only the carotid with the highest TBR was included for analysis. Results for the carotid arteries are therefore based on n = 9 DTC patients and n = 5 euthyroid subjects. In one lean DTC patient, VAT could not be analysed.

Arterial TBRs in DTC patients

The SUVs for 18F-FDG uptake are given in supplementary table 1. The TBRmax per vascular territory can be found in Table 2. The meanTBRmax for all aortic territories taken together increased from 1.6 ± 0.2 to 1.8 ± 0.2 (p = 0.058) after levothyroxine treatment. Similar results were also found for all individual arterial territories, with the exception of the carotids, in which no difference between 18F-FDG uptake was found between hypothyroid state and TSH suppression. In the aortic arch and thoracic descending aorta, the increase in meanTBRmax during TSH suppression reached statistical significance (p = 0.031 and p = 0.021 respectively). In one patient, fT4 and TSH-values were both within the normal range at the time of the second scan (TSH 0.8 mU/l; fT4 14.2 pmol/l). Exploratory exclusion of this patient increased statistical significance for all TBR analyses.
Table 2

TBRmax per vascular territory

 

Hypothyroidism

TSH suppression

P value

Euthyroid

Carotidsa

1.7 (0.2)*

1.7 (0.3)*

0.943

1.3 (0.2)

Ascending aorta

1.7 (0.2)

1.8 (0.2)

0.340

1.7 (0.2)

Aortic arch

1.7 (0.2)

1.9 (0.2)*

0.031

1.5 (0.3)

Thoracic aorta

1.6 (0.2)

1.9 (0.2)*

0.021

1.7 (0.2)

Abdominal aorta

1.4 (0.2)

1.6 (0.2)

0.105

1.6 (0.2)

All vessels

1.6 (0.2)

1.8 (0.2)*

0.058

1.6 (0.2)

Bold font indicates a statistically significant difference between hypothyroidism and TSH-suppression.

Whole vessel (territory) analysis for TBRmax is given, depicted as the mean with the standard deviation between brackets. For hypothyroidism these values are based on n = 9, for euthyroid n = 5 and for TSH suppression n = 10. For all other vessel territories, the mean TBRmax is given based on n = 7 for euthyroid state and n = 10 for hypothyroidism and TSH-suppressed state

* indicates a significant difference with euthyroid patients of p < 0.05

athe highest value of both carotids was selected for further analysis

Arterial TBRs in a control group of euthyroid subjects

Notwithstanding the higher number of cardiovascular risk factors in the euthyroid group, arterial TBRs were always lower in this group compared to the TBRs measured during TSH suppression in the DTC population. This was statistically significant in the carotids, aortic arch, and descending thoracic aorta (See Table 2 and Fig. 1). In addition, the arterial TBRs of euthyroid subjects were also significantly lower in comparison to the hypothyroid state in the carotid arteries and for the TBRmax in the aortic arch, but similar in the ascending and descending thoracic aorta, and not-significantly higher in the abdominal aorta (See Table 2 and Fig. 1). When all vascular territories were combined, there was a significant difference between the TBRs of euthyroid subjects and those under TSH suppression (p = 0.018 for TBRmax).
Fig. 1

Dot plot of TBRmax per vascular territory during different thyroid hormone states. Mean TBRmax values are depicted with their standard deviation superimposed on the individual data points for the DTC patients during hypothyroidism and TSH suppression, and for euthyroid controls. TBRmax values are based on n = 10 for both hypothyroidism and TSH suppression for all aortic segments, and for the carotids during TSH suppression. TBRmax for the carotids during hypothyroidism is based on n = 9. Average TBRmax values for euthyroid state are based on n = 7 for all aortic segments and n = 5 for the carotids

TBRs in spleen, bone marrow, and white adipose tissue

In agreement with the pattern of 18F-FDG uptake in the arteries, BM also showed significantly higher TBRs during TSH suppression (meanTBRmax 2.0 ± 0.3 vs 1.7 ± 0.3, p = 0.014). Differences of the 18F-FDG uptake between the thyroid hormone states were only slight in the spleen, VAT as well as SAT at the level of the xiphoid bone, and did not reach statistical significance. However, 18F-FDG uptake in nuchal SAT showed a trend towards lower TBRs during TSH suppression, in contrast to the findings in the vasculature. See Table 3 for details.
Table 3

TBRmax of the spleen, bone marrow, and adipose tissue

 

Hypothyroidism

TSH suppression

P value

Spleen

1. 7 (0.3)

1.7 (0.2)

0.644

Bone marrow

1.7 (0.3)

2.0 (0.3)

0.014

SAT chest

0.4 (0.2)

0.4 (0.2)

0.550

SAT neck

0.4 (0.1)

0.4 (0.1)

0.053

VATa

0.4 (0.2)

0.5 (0.1)

0.943

Bold font indicates a statistically significant difference between hypothyroidism and TSH-suppression.

TBRs are given as mean and standard deviation between brackets.

an = 9

Correlations between TBRs and CRP

We tested for correlations between different measures of 18F-FDG uptake and CRP blood levels. However, only a few of the tested correlations reached statistical significance. There were no significant correlations between CRP and the arterial SUVs. CRP was only significantly correlated to the TBRmax of the carotids, the ascending aorta the aortic arch, and when all vessel territories were combined for the hypothyroid period. No significant correlation between CRP and any of the 18F-FDG uptake measures could be found during TSH suppression or in euthyroid participants. See Table 4.
Table 4

Correlation between TBRs and CRP

TBRmax

CRP levels

Hypothyroidism

TSH suppression

Euthyroid

Carotid

0.822**

0.374

−0.148

Ascending aorta

0.721*

0.038

0.397

Aortic arch

0.708*

0.316

0.440

Thoracic aorta

0.398

−0.114

0.145

Abdominal aorta

0.299

0.549

0.093

All vessels

0.785**

0.331

0.360

Spleen

0.663

−0.256

 

Bone marrow

0.138

−0.549

 

VAT

−0.074

−0.151

 

SAT neck

0.140

−0.134

 

SAT xyphoid

−0.244

−0.327

 

Depicted are the Spearman rho (ρ) coefficients

*signifies statistical significance with a p value < 0.05

**indicates a p value < 0.01

Discussion

In this explorative study, we were able to show that vascular TBRs, as a measure for arterial inflammation, are higher under TSH-suppressive medication than during hypothyroidism, indicating a negative impact of TSH suppression on atherosclerosis. To the best of our knowledge, changes in arterial inflammation due to thyroid hormone imbalance have never been studied before in humans in vivo. The inclusion of thyroid cancer patients enabled us to study the effects of pathological thyroid hormone levels on both ends of the spectrum within the same patient. This study design controls for differences in causation of thyroid hormone imbalance, but also for the variability in the necessary levothyroxine dose for each patient to establish adequate TSH suppression, since patients served as their own control.

We chose to focus on TBRs as an outcome measure, since TBR has been proposed as the more relevant measurement for arterial inflammation as it normalizes SUV values for 18F-FDG blood pool activity [16]. As mentioned in the Methods section, ROIs were drawn to encompass the entire vessel wall including the lumen, as is a common and accepted procedure in analyses of vessel wall inflammation. This approach is mainly used to address the limited resolution of PET/CT and the chance of spill-in and spill-out. In arteries without a high-degree stenosis, such as probably most commonly seen in our population, blood pool activity is a major contributor to the vessel wall SUVs. As such, this will generally result in an underestimation of the activity in the vascular wall, and fluctuations in blood pool activity can greatly affect results. Correction for the blood pool activity is therefore a necessity. This is of particular relevance in the current study, since thyroid hormone has a wide range of effects on multiple tissues and amongst others increases general glucose uptake, glycolysis, gluconeogenesis and tissue blood flow [17]. These effects will likely affect 18F-FDG metabolism as well. For instance, through an increased general energy expenditure [14] and increased glucose transporters (GLUT) expression in different tissues, such as the muscles, liver and brain [18, 19, 20], it is likely that competition for 18F-FDG is increased. Consequently, the distribution of 18F-FDG uptake is increased throughout the body, resulting in a lower blood pool activity and lower absolute uptake in specific tissues. In addition, thyroid hormone may also affect renal function and increase blood volume. However, although 18F-FDG is cleared by the kidneys, increased diuresis by means of saline infusion or diuretics did not effect 18F-FDG blood activity in rats [21]. Additionally, 18F-FDG distribution was not significantly affected in patients with a disrupted renal function [22]. Therefore, we assume the lower blood pool activity during TSH suppresion to rather be an effect of an altered distribution of 18F-FDG throughout the body. TBR is used to correct for the distributional spread of 18F-FDG. SUV already corrects for injected dose, patient weight, and decay. In a way, TBR is not a more accurate representation of the absolute uptake than SUV [23], but it is, as its name suggests, a ratio between the uptake in the target, the vessel wall (including the lumen), and the blood pool activity (in a nearby vein). Even though the absolute uptake in the vessel walls may have been lower after thyroxine depletion, the relative uptake was higher. Earlier research showed TBR to better correlate to the clinical risk of cardiovascular events and to the effects of dedicated treatment [4, 24], and it is therefore recommended in vascular research [16]. Concurrently, we found CRP levels to correlate to vascular TBRs, but not to vascular SUVs during hypothyroidism.

Previous research has mainly focused on the harmful effects of hypothyroidism on atherosclerosis [25, 26, 27]. Strong evidence exists that hypothyroidism raises the risk for the onset and progression of atherosclerosis due to an increased incidence of cardiovascular risk factors such as hypertension and a disturbed lipid balance [26, 27]. In concurrence with those findings, we found both blood pressure and plasma lipid levels (FFA and glycerol) to be higher during hypothyroidism than during TSH suppression. In addition, (subclinical) hypothyroidism has also been associated with increased systemic low-grade inflammation, as measured by elevated CRP and interleukin levels, compared to euthyroid patients [28]. In agreement with this, surgically removed carotid atherosclerotic plaques of these patients had a higher macrophage content compared to those of euthyroid patients [28]. In line with those results, other studies found a possible anti-inflammatory effect of thyroid hormone [25, 29]. In vitro, thyroid hormone decreased the migration of bone-marrow-derived monocytes from hematopoietic tissues to local inflammatory processes [29]. Further suggesting an anti-inflammatory effect of thyroid hormones, additional knockout of the thyroid hormone receptor alpha in apoE knockout mice, a commonly used atherosclerosis model, increased both atherosclerotic plaque size, and plaque inflammation [25]. Our finding that CRP levels correlate to vascular TBRs during hypothyroidism seems to underline an inflammatory effect of hypothyroidism.

In contrast, the results of our study also seem to plead for a pro-inflammatory effect of increased thyroid hormone levels and/or TSH suppression. Although we were unable to gain histological proof that the increased arterial TBRs were indeed caused by an increased number of macrophages in the vascular wall or macrophage activation, the elevated levels of CRP during TSH suppression indicate a role for inflammation. During hypothyroidism, CRP levels were detectable (> 1.0 mg/l) in 40% of the patients and similar to the CRP levels in the euthyroid participants, but during TSH suppression CRP levels were detectable in in 60% of the patients and the mean serum levels were significantly higher during TSH suppression than during hypothyroidism. Previous research has shown that increased CRP levels correlate with a significantly increased risk of subsequent cardiovascular events [30] and with arterial 18F-FDG uptake [31, 32].

In our study population, levothyroxine treatment modified cardiovascular risk factors classically related to hypothyroidism [26, 27], suggesting an increase of these risk factors during hypothyroidism. The observed decrease in blood pressure and plasma lipids after levothyroxine treatment, combined with the increased uptake of 18F-FDG in the vascular wall, might suggest that a different mechanism is responsible for the inflammatory changes in the vascular wall during TSH suppression as compared to hypothyroidism. Previously published preclinical studies have also shown direct effects of thyroid hormone on vascular wall cells [33, 34]. For instance, rats with induced thyrotoxicosis showed markers for increased oxidative stress and lipid peroxidation in addition to increased arterial stiffness, due to changes in vascular smooth muscle cell and elastin and collagen content in the vessel wall [33, 34]. Furthermore, elevated markers of endothelial activation were observed in patients with hyperthyroidism due to Graves’ disease [35, 36]. The exact mechanism underlying the higher arterial uptake of 18F-FDG during TSH suppression remains, therefore, to be investigated.

In DTC patients, lower TSH levels have been related to an increased risk of cardiovascular mortality [13], and other clinical studies have shown thyroid hormone levels to be related to different measurements for atherosclerotic disease burden [2, 37, 38]. For instance, high fT4 levels have been related to increased arterial stiffness [2] and low TSH levels to increased carotid intima-media thickness [37]. In a large population study, Zhang et al. [38] found both low-normal fT4 and low-normal TSH levels to be related to higher coronary artery calcium (CAC) scores [38]. The authors suggest that fT4 and TSH might influence atherosclerosis via different direct and indirect mechanisms, since TSH receptors are present along with thyroid hormone receptors in vascular smooth muscle cells. Although this study only included participants with hormone levels within the normal range, these findings might indicate that extreme hormone levels on both ends of the spectrum play a role in the development of atherosclerosis. Thus, the correlation between thyroid hormone levels and vascular disease might indeed be U-shaped [2]. This suspicion was confirmed by the results of our study when we compared arterial TBRs of euthyroid patients with those of our DTC population. Arterial TBRs were generally lower in the euthyroid group compared to both hypothyroidism and TSH suppression, despite their higher cardiovascular risk profile compared to the DTC study population. This finding supports the hypothesis that both hypothyroidism and hyperthyroidism predispose to atherosclerosis.

The results of previously published 18F-FDG-PET studies indicate that the hematopoietic organs are involved in the systemic inflammatory response in atherosclerosis, as the 18F-FDG uptake in the spleen and the bone marrow showed a significant correlation with arterial inflammation [8, 9]. In accordance with these results, we also found significantly higher bone marrow TBRs during TSH suppression compared to the hypothyroid situation, suggesting increased hematopoietic activity, potentially in the context of the observed increased arterial inflammation.

Additionally, it must be pointed out that although fT4 levels were above reference values in 90% of the patients, perfect TSH suppression was not yet confirmed by TSH values in 40% of the patients. In health, TSH responds with a logarithmic increase compared to the fT4 decrease and vice versa [12]. As such, TSH is more sensitive to endogenous thyroid disease than fT4 levels. However, its response is not instant to levothyroxine treatment and it is not uncommon to await further TSH decrease while maintaining a stable levothyroxine dose. Our findings result in the expectation that with further TSH decrease and longer duration of TSH suppression, vascular inflammation would only increase further. TSH suppression in DTC patients is a long-term treatment and previous research points to negative effects on cardiac physiology and bone density [12]. Thus far, studies on a potential increased risk of cardiovascular death in DTC patients with TSH suppression have been inconclusive [12], but our findings agree with the recent more critical view on TSH suppressive therapy, pointing to a personalized approach [10, 11].

Limitations

This was an exploratory study, and as such it is limited by a small population sample. It is possible that some of our analyses did not reach statistical significance because the study might have been underpowered. Therefore, our findings need to be confirmed in a larger prospective study.

A drawback of our study design is the possibility of a so-called period effect, since TSH suppression always followed hypothyroidism and the duration of each period differed. Because a longer time period of TSH-suppressive therapy was needed to achieve stable thyroid hormone levels, the period between the start of levothyroxine treatment and the second scan was longer than the period between thyroidectomy and the first scan. We can therefore not completely exclude the possibility that the TBRs were higher during TSH suppression because the period of TSH suppression was longer. However, our findings seem to be in contrast to earlier studies showing a decrease in vascular disease with thyroid hormone replacement therapy in (subclinical) hypothyroidism [39, 40]. This rather supports a detrimental effect of increased thyroid hormones on arterial inflammation.

Since our scan protocol was primarily aimed at imaging cold-induced BAT activity, it differs from arterial imaging guidelines on PET imaging in atherosclerosis [16, 41]. However, since all patients served as their own control, this should not have biased our results to a relevant degree.

The inclusion of diabetes-prone participants as euthyroid controls should be considered as merely exploratory. As mentioned before, these subjects cannot be considered as fully healthy controls, but neither can they be considered as atherosclerotic.

Conclusions

To the best of our knowledge, this is the first study linking disturbed thyroid hormone levels to arterial inflammation in vivo. This explorative study shows arterial TBRs, as a measure for arterial inflammation, to be higher during TSH suppression than during hypothyroidism, and arterial TBRs to be higher during both ends of thyroid hormone imbalance than during the euthyroid state. Future prospective and well-powered studies need to confirm our results.

Notes

Acknowledgements

The authors would like to thank G.A.J.C Crombag, MD, for her support with creating Fig. 1.

Funding

This study was financially supported in part by the Stichting de Weijerhorst (E.Bo., J.E.W., J.B.). M.d.L. was funded by a Diabetes Fonds Project Grant (2012.00.1525). W.D.v.M.L. was funded by EU FP7, project DIABAT (HEALTH-F2-2011-278373), and by the Dutch Organization for Scientific Research (NWO-ZonMw 91209037).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The local medical ethics committee (azM/UM) approved the study protocol of both original studies (METC 11-3-081 for the DTC patients and METC 13-3-058 for the euthyroid participants) and its additional analysis (METC 2018-0445). All study procedures in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in this study.

Supplementary material

259_2019_4292_MOESM1_ESM.docx (64 kb)
Supplementary table 1 (DOCX 63 kb)

References

  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.  https://doi.org/10.1161/CIR.0000000000000350.Google Scholar
  2. 2.
    Delitala AP, Orru M, Filigheddu F, Pilia MG, Delitala G, Ganau A, et al. Serum free thyroxine levels are positively associated with arterial stiffness in the SardiNIA study. Clin Endocrinol. 2015;82:592–7.  https://doi.org/10.1111/cen.12532.CrossRefGoogle Scholar
  3. 3.
    Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5:69–77.  https://doi.org/10.1161/CIRCIMAGING.110.959478.CrossRefGoogle Scholar
  4. 4.
    Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6:1250–9.  https://doi.org/10.1016/j.jcmg.2013.08.006.CrossRefGoogle Scholar
  5. 5.
    Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642–7.  https://doi.org/10.1161/01.STR.0000190896.67743.b1.CrossRefGoogle Scholar
  6. 6.
    Bucerius J, Mani V, Wong S, Moncrieff C, Izquierdo-Garcia D, Machac J, et al. Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging. 2014;41:934–45.  https://doi.org/10.1007/s00259-013-2653-y.CrossRefGoogle Scholar
  7. 7.
    Vanfleteren LE, van Meerendonk AM, Franssen FM, Wouters EF, Mottaghy FM, van Kroonenburgh MJ, et al. A possible link between increased metabolic activity of fat tissue and aortic wall inflammation in subjects with COPD. A retrospective 18F-FDG-PET/CT pilot study. Respir Med. 2014;108:883–90.  https://doi.org/10.1016/j.rmed.2014.04.001.CrossRefGoogle Scholar
  8. 8.
    Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015;8:121–30.  https://doi.org/10.1016/j.jcmg.2014.10.009.CrossRefGoogle Scholar
  9. 9.
    Kim EJ, Kim S, Kang DO, Seo HS. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging. Circ Cardiovasc Imaging. 2014;7:454–60.  https://doi.org/10.1161/CIRCIMAGING.113.001093.CrossRefGoogle Scholar
  10. 10.
    Werkgroep_Richtlijn_Schildkliercarcinoom. Richtlijn: Schildkliercarcinoom 2.0. 2.0 ed. Integraal Kankercentrum Nederland (IKNL), Utrecht; 2015.Google Scholar
  11. 11.
    American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.  https://doi.org/10.1089/thy.2009.0110.CrossRefGoogle Scholar
  12. 12.
    Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20:135–46.  https://doi.org/10.1089/thy.2009.0311.CrossRefGoogle Scholar
  13. 13.
    Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046–53.  https://doi.org/10.1200/JCO.2013.49.1043.CrossRefGoogle Scholar
  14. 14.
    Broeders EP, Vijgen GH, Havekes B, Bouvy ND, Mottaghy FM, Kars M, et al. Thyroid hormone activates brown adipose tissue and increases non-shivering thermogenesis--a cohort study in a group of thyroid carcinoma patients. PLoS One. 2016;11:e0145049.  https://doi.org/10.1371/journal.pone.0145049.CrossRefGoogle Scholar
  15. 15.
    de Ligt M, Bruls YMH, Hansen J, Habets MF, Havekes B, Nascimento EBM, et al. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab. 2018;12:39–47.  https://doi.org/10.1016/j.molmet.2018.04.004.CrossRefGoogle Scholar
  16. 16.
    Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, et al. Position paper of the cardiovascular committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging. 2016;43:780–92.  https://doi.org/10.1007/s00259-015-3259-3.CrossRefGoogle Scholar
  17. 17.
    Hall J. Guyton and Hall textbook of medical physiology. Thirteenth ed. Philadelphia: Elsevier;2016.Google Scholar
  18. 18.
    Mooradian AD, Girgis W, Shah GN. Thyroid hormone-induced GLUT-1 expression in rat cerebral tissue: effect of age. Brain Res. 1997;747:144–6.CrossRefGoogle Scholar
  19. 19.
    Shetty M, Kuruvilla AK, Ismail-Beigi F, Loeb JN. Stimulation of glucose transport in clone 9 cells by insulin and thyroid hormone: role of GLUT-1 activation. Biochim Biophys Acta. 1996;1314:140–6.CrossRefGoogle Scholar
  20. 20.
    Weinstein SP, O’Boyle E, Haber RS. Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle — the role of GLUT4 glucose transporter expression. Diabetes. 1994;43:1185–9.CrossRefGoogle Scholar
  21. 21.
    Kosuda S, Fisher S, Wahl RL. Animal studies on the reduction and/or dilution of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) activity in the urinary system. Ann Nucl Med. 1997;11:213–8.CrossRefGoogle Scholar
  22. 22.
    Akers SR, Werner TJ, Rubello D, Alavi A, Cheng G. 18F-FDG uptake and clearance in patients with compromised renal function. Nucl Med Commun. 2016;37:825–32.  https://doi.org/10.1097/MNM.0000000000000513.CrossRefGoogle Scholar
  23. 23.
    Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med. 2015;56:552–9.  https://doi.org/10.2967/jnumed.114.142596.CrossRefGoogle Scholar
  24. 24.
    Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62:909–17.  https://doi.org/10.1016/j.jacc.2013.04.066.CrossRefGoogle Scholar
  25. 25.
    Billon C, Canaple L, Fleury S, Deloire A, Beylot M, Dombrowicz D, et al. TRalpha protects against atherosclerosis in male mice: identification of a novel anti-inflammatory property for TRalpha in mice. Endocrinology. 2014;155:2735–45.  https://doi.org/10.1210/en.2014-1098.CrossRefGoogle Scholar
  26. 26.
    Pasqualetti G, Tognini S, Polini A, Caraccio N, Monzani F. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? J Clin Endocrinol Metab. 2013;98:2256–66.  https://doi.org/10.1210/jc.2012-3818.CrossRefGoogle Scholar
  27. 27.
    Ichiki T. Thyroid hormone and vascular remodeling. J Atheroscler Thromb. 2016;23:266–75.  https://doi.org/10.5551/jat.32755.CrossRefGoogle Scholar
  28. 28.
    Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96:1015–20.  https://doi.org/10.1210/jc.2010-1382.CrossRefGoogle Scholar
  29. 29.
    Perrotta C, Buldorini M, Assi E, Cazzato D, De Palma C, Clementi E, et al. The thyroid hormone triiodothyronine controls macrophage maturation and functions: protective role during inflammation. Am J Pathol. 2014;184:230–47.  https://doi.org/10.1016/j.ajpath.2013.10.006.CrossRefGoogle Scholar
  30. 30.
    Libby P, Willerson JT, Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med. 2004;351:295–8. author reply -8.CrossRefGoogle Scholar
  31. 31.
    Yoo HJ, Kim S, Park MS, Yang SJ, Kim TN, Seo JA, et al. Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: analysis with 18F-FDG PET. J Nucl Med. 2011;52:10–7.  https://doi.org/10.2967/jnumed.110.080838.CrossRefGoogle Scholar
  32. 32.
    Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, et al. Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol. 2011;31:944–9.  https://doi.org/10.1161/ATVBAHA.110.220673.CrossRefGoogle Scholar
  33. 33.
    Moulakakis KG, Sokolis DP, Perrea DN, Dosios T, Dontas I, Poulakou MV, et al. The mechanical performance and histomorphological structure of the descending aorta in hyperthyroidism. Angiology. 2007;58:343–52.  https://doi.org/10.1177/0003319707301759.CrossRefGoogle Scholar
  34. 34.
    Moulakakis KG, Poulakou MV, Paraskevas KI, Dontas I, Vlachos IS, Sokolis DP, et al. Hyperthyroidism is associated with increased aortic oxidative DNA damage in a rat model. In Vivo. 2007;21:1021–6.Google Scholar
  35. 35.
    Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid. 2001;11:153–60.  https://doi.org/10.1089/105072501300042820.CrossRefGoogle Scholar
  36. 36.
    Deng J, Zhao R, Zhang Z, Wang J. Changes in vasoreactivity of rat large- and medium-sized arteries induced by hyperthyroidism. Exp Toxicol Pathol. 2010;62:317–22.  https://doi.org/10.1016/j.etp.2009.04.007.CrossRefGoogle Scholar
  37. 37.
    Volzke H, Robinson DM, Schminke U, Ludemann J, Rettig R, Felix SB, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab. 2004;89:2145–9.  https://doi.org/10.1210/jc.2003-031028.CrossRefGoogle Scholar
  38. 38.
    Zhang Y, Kim BK, Chang Y, Ryu S, Cho J, Lee WY, et al. Thyroid hormones and coronary artery calcification in euthyroid men and women. Arterioscler Thromb Vasc Biol. 2014;34:2128–34.  https://doi.org/10.1161/ATVBAHA.114.303889.CrossRefGoogle Scholar
  39. 39.
    Deyneli O, Akpinar IN, Mericliler OS, Gozu H, Yildiz ME, Akalin NS. Effects of levothyroxine treatment on insulin sensitivity, endothelial function and risk factors of atherosclerosis in hypothyroid women. Ann Endocrinol (Paris). 2014;75:220–6.  https://doi.org/10.1016/j.ando.2014.06.002.CrossRefGoogle Scholar
  40. 40.
    Cakal E, Turgut AT, Demirbas B, Ozkaya M, Cakal B, Serter R, et al. Effects of L-thyroxine replacement therapy on carotid intima-media thickness in patients with primary hypothyroidism. Exp Clin Endocrinol Diabetes. 2009;117:294–300.  https://doi.org/10.1055/s-0028-1085998.CrossRefGoogle Scholar
  41. 41.
    Gholami S, Salavati A, Houshmand S, Werner TJ, Alavi A. Assessment of atherosclerosis in large vessel walls: a comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol. 2015;22:468–79.  https://doi.org/10.1007/s12350-015-0069-8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Ellen Boswijk
    • 1
    • 2
  • Karin J. C. Sanders
    • 3
    • 4
  • Evie P. M. Broeders
    • 5
  • Marlies de Ligt
    • 3
  • Guy H. E. J. Vijgen
    • 6
  • Bas Havekes
    • 7
  • Alma M. A. Mingels
    • 8
  • Roel Wierts
    • 1
  • Wouter D. van Marken Lichtenbelt
    • 3
  • Patrick Schrauwen
    • 3
  • Felix M. Mottaghy
    • 1
    • 9
  • Joachim E. Wildberger
    • 1
    • 2
  • Jan Bucerius
    • 1
    • 2
    • 9
    Email author
  1. 1.Department of Radiology and Nuclear MedicineMaastricht University Medical Centre (MUMC+)MaastrichtThe Netherlands
  2. 2.Cardiovascular Research Institute Maastricht (CARIM)Maastricht UniversityMaastrichtThe Netherlands
  3. 3.Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM)Maastricht UniversityMaastrichtThe Netherlands
  4. 4.Department of Respiratory MedicineSchool of Nutrition and Translational Research in Metabolism (NUTRIM)MaastrichtThe Netherlands
  5. 5.Department of Family MedicineAmsterdam University Medical Centre (Amsterdam UMC)Amsterdamthe Netherlands
  6. 6.Department of SurgeryFranciscusRotterdamThe Netherlands
  7. 7.Department of Internal Medicine, Division of EndocrinologyMaastricht University Medical Centre (MUMC+)MaastrichtThe Netherlands
  8. 8.Department of Clinical Chemistry, Central Diagnostic LaboratoryMaastricht University Medical Centre (MUMC+)MaastrichtThe Netherlands
  9. 9.Department of Nuclear MedicineUniversity Hospital RWTH AachenAachenGermany

Personalised recommendations